Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Lung Neoplasms 12Multiple Myeloma 11Lymphoma 10Neoplasm Metastasis 9Melanoma 7Leukemia, Myeloid, Acute 7Prostatic Neoplasms 6Neuroblastoma 6Carcinoma, Non-Small-Cell Lung 6Wilms Tumor 5Medulloblastoma 5Lymphoma, Non-Hodgkin 5Fallopian Tube Neoplasms 5Burkitt Lymphoma 5Breast Neoplasms 5Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Rhabdoid Tumor 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Osteosarcoma 4Neuroectodermal Tumors, Primitive, Peripheral 4Histiocytosis, Langerhans-Cell 4Hepatoblastoma 4Glioma 4Ependymoma 4Central Nervous System Neoplasms 4Sarcoma, Kaposi 3Sarcoma 3

Interventions

ribociclib 1cabozantinib 1X-Rays 1Specimen Handling 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Non functioning pancreatic endocrine tumor × Specimen Handling × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡